The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Aims
The importance of programmed cell death ligand 1 (PD‐L1) expression has emerged in clinical trials of PD‐L1 target therapy in renal cell carcinoma (RCC). This study compares PD‐L1 assays in RCC.
Methods and results
Two US Food and Drug Administration‐approved PD‐L1 assays (22C3 and SP142) and one research‐use only antibody (E1L3N) were used in a retrospective cohort of 591 patients with RCC...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.